<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1925">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05606341</url>
  </required_header>
  <id_info>
    <org_study_id>20-00267</org_study_id>
    <nct_id>NCT05606341</nct_id>
  </id_info>
  <brief_title>Innate Immunity Stimulation Via TLR9 in Early AD</brief_title>
  <official_title>Phase 1 Clinical Trial of Innate Immunity Stimulation Via TLR9 in Early Alzheimer's Disease (AD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alzheimer's Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single-center, double-blind, placebo-controlled study will recruit in total 39&#xD;
      participants with either Mild Cognitive Impairment due to Alzheimer's disease (MCI) or Mild&#xD;
      Alzheimer's disease dementia (mild AD). There will be 3 Dose levels. An initial cohort of 13&#xD;
      subjects will be randomized to a Dose level 1 (0.1 mg/kg vs. placebo) lasting 8 weeks. An&#xD;
      additional 13 subjects will be recruited and randomized into Dose level 2 (0.25 mg/kg vs.&#xD;
      placebo) for 8 weeks and 13 subjects for the last Dose level 3 (0.5 mg/kg vs. placebo) for 8&#xD;
      weeks. The primary objective will be to assess safety and tolerability of CpG 1018.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2022</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomly allocated in a blinded fashion to receive s.c. injection of either CpG ODN (dose level 1, 0.1 mg/kg) or placebo (saline). Dose escalation will occur after 10 weeks after the last injection in a new subject cohort, and will be based on the safety data and immunostimulatory assessments at previous dose level cohorts.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patient-Reported Adverse Events (AEs)</measure>
    <time_frame>Up to Week 18</time_frame>
    <description>AEs defined as any symptom, sign, illness or experience that develops or worsens in severity during the course of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Rheumatoid Factor (RF) Confirmed by Autoimmunity Marker Screening Test Result</measure>
    <time_frame>Up to Week 18</time_frame>
    <description>Evaluation of RF in patient blood samples at Baseline, Day 56, Week 14 and Week 18.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Antinuclear Antibody (ANA) Confirmed by Autoimmunity Marker Screening Test Result</measure>
    <time_frame>Up to Week 18</time_frame>
    <description>Evaluation of ANA in patient blood samples at Baseline, Day 56, Week 14 and Week 18.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Antineutrophil Cytoplasmic Antibody (ANCA) Confirmed by Autoimmunity Marker Screening Test Result</measure>
    <time_frame>Up to Week 18</time_frame>
    <description>Evaluation of ANCA in patient blood samples at Baseline, Day 56, Week 14 and Week 18.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Amyloid-Related Imaging Abnormalities-Haemosiderin (ARIA-H) Confirmed by Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Up to Week 14</time_frame>
    <description>Evaluation of ARIA-H at Baseline and Week 14 using 3T PET/MR Siemens Biograph system.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Amyloid-Related Imaging Abnormalities-Edema (ARIA-E) Confirmed by Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Up to Week 14</time_frame>
    <description>Evaluation of ARIA-E at Baseline and Week 14 using 3T PET/MR Siemens Biograph system.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in AD Assessment Scale Cognitive Subscale (ADAS-Cog-13) Scores</measure>
    <time_frame>Baseline, Week 18</time_frame>
    <description>13-item self-assessment measuring levels of cognitive and non-cognitive dysfunctions from mild to severe. Total scores range from 0 to 85. Lower scores indicate greater cognitive performance. A decrease in scores indicates cognitive performance improved during the observational period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in AD Cooperative Study-Activities of Daily Living Inventory, Mild Cognitive Impairment version (ADCS-ADL-MCI) Scores</measure>
    <time_frame>Baseline, Week 18</time_frame>
    <description>18-item questionnaire measuring a participant's basic and instrumental activities of daily living over the previous month. Total scores range from 0-53, where higher scores indicate greater competence in performing activities. An increase in scores indicates competence increased during the observational period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Columbia-Suicide Severity Rating Scale (C-SSRS) Scores</measure>
    <time_frame>Baseline, Week 18</time_frame>
    <description>C-SSRS systematically tracks suicidal ideation and behavior. The total score range is 0 (no ideation is present) to 5 (active suicidal ideation with specific plan and intent). A decrease in scores indicates suicidal ideation and behavior decreased during the observational period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Global Clinical Dementia Rating (CDR-Global)</measure>
    <time_frame>Baseline, Week 18</time_frame>
    <description>5-point questionnaire assessing six domains of cognitive and functional performance applicable to Alzheimer's disease and related dementias: Memory, Orientation; Judgement &amp; Problem Solving; Community Affairs; Home &amp; Hobbies; and Personal Care. Higher scores indicate greater severity of dementia: 0= Normal, 0.5=very mild dementia, 1=mild dementia, 2=moderate dementia, 3=severe dementia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Montreal Cognitive Assessment (MoCa) Score</measure>
    <time_frame>Baseline, Week 18</time_frame>
    <description>30-item assessment of global cognitive function. Total scores range from 0 to 30, with higher scores indicating greater cognitive function. Scores of 26 and higher are consider to be normal. An increase in scores indicates cognitive function increased during the observational period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Amyloid Biomarker Concentration</measure>
    <time_frame>Baseline, Week 18</time_frame>
    <description>Amyloid biomarker concentration detected via plasma analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cerebral Spinal Fluid (CSF) Amyloid Biomarker Concentration</measure>
    <time_frame>Baseline, Week 18</time_frame>
    <description>Amyloid biomarker concentration detected via CSF analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Tau Biomarker Concentration</measure>
    <time_frame>Baseline, Week 18</time_frame>
    <description>Tau biomarker concentration detected via plasma analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CSF Tau Biomarker Concentration</measure>
    <time_frame>Baseline, Week 18</time_frame>
    <description>Tau biomarker concentration detected via CSF analysis.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Alzheimer Dementia</condition>
  <arm_group>
    <arm_group_label>CpG 1018 0.1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 injections at Day 1, Week 4, and Week 8.&#xD;
Treatment administered as morning injection of dose 0.1mg/kg, followed by 1-hour post-dose observation period to check for injection site reaction and/or adverse reactions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CpG 1018 0.25 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 injections at Day 1, Week 4, and Week 8.&#xD;
Treatment administered as morning injection of dose 0.25 mg/kg, followed by 1-hour post-dose observation period to check for injection site reaction and/or adverse reactions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CpG 1018 0.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 injections at Day 1, Week 4, and Week 8.&#xD;
Treatment administered as morning injection of dose 0.5 mg/kg, followed by 1-hour post-dose observation period to check for injection site reaction and/or adverse reactions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 injections of sterile saline at Day 1, Week 4, and Week 8, followed by 1-hour post-dose observation period to check for injection site reaction and/or adverse reactions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CpG1018</intervention_name>
    <description>0.1 mg/kg dose administered via subcutaneous injection.&#xD;
TLR9 agonist supplied by Dynavax Technologies Inc.</description>
    <arm_group_label>CpG 1018 0.1 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CpG1018</intervention_name>
    <description>0.25 mg/kg dose administered via subcutaneous injection.&#xD;
TLR9 agonist supplied by Dynavax Technologies Inc.</description>
    <arm_group_label>CpG 1018 0.25 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CpG1018</intervention_name>
    <description>0.5 mg/kg dose administered via subcutaneous injection.&#xD;
TLR9 agonist supplied by Dynavax Technologies Inc.</description>
    <arm_group_label>CpG 1018 0.5 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterile saline injection supplied by the NYU Investigational Pharmacy.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 65-85 years of age&#xD;
&#xD;
          2. MCI due to AD or mild AD dementia per NIA-AA specified criteria published in 2018&#xD;
&#xD;
          3. Montreal Cognitive Assessment (MoCA) score â‰¥17 AND;&#xD;
&#xD;
          4. Positive Florbetaben PET amyloid scan, or other positive PET amyloid scan performed&#xD;
             within one year of study enrollment&#xD;
&#xD;
          5. Must be able to provide consent or assent (If applicable).&#xD;
&#xD;
          6. Must be willing and able to participate in all study related procedures.&#xD;
&#xD;
          7. Must have a reliable study partner to provide information on the subject's cognitive&#xD;
             and functional status. Study partner must have sufficient contact with the subject, as&#xD;
             determined by the PI, and be available to accompany the subject to clinic visits or by&#xD;
             phone.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of psychiatric illness (e.g. hallucinations, major depression, suicidal&#xD;
             ideation or delusions) that could interfere with completion of study related&#xD;
             procedures as determined by PI&#xD;
&#xD;
          2. History of autoimmune disorders or antibody-mediated disease, severe asthma, or other&#xD;
             serious infection or systemic illness, as determined by PI&#xD;
&#xD;
          3. Use of corticosteroids or immunosuppressive drugs within 30 days of study entry&#xD;
&#xD;
          4. History of splenectomy&#xD;
&#xD;
          5. Renal impairment&#xD;
&#xD;
          6. Use of chloroquine within 8 weeks of study entry&#xD;
&#xD;
          7. Inability to undergo MRI imaging&#xD;
&#xD;
          8. History of TIA, stroke or seizures within 12 months of screening&#xD;
&#xD;
          9. Any neurological condition other than AD that could contribute to cognitive impairment&#xD;
             (including related to possible &quot;long COVID&quot;) as determined by PI&#xD;
&#xD;
         10. Participation in any other current AD investigational interventional trial&#xD;
&#xD;
         11. Current use of an anti-coagulant&#xD;
&#xD;
         12. Current use of drugs that are major substrates of cytochrome P450 (CYP) enzyme 1A2&#xD;
&#xD;
         13. Recent exposure to COVID-19 infection within 14 days or recent onset of symptoms&#xD;
             within 14 days that may be related to COVID-19 infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arjun Masurkar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alok Vedvyas</last_name>
    <phone>212-263-2048</phone>
    <email>Alok.Vedvyas@nyulangone.org</email>
  </overall_contact>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 1, 2022</study_first_submitted>
  <study_first_submitted_qc>November 1, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2022</study_first_posted>
  <last_update_submitted>November 1, 2022</last_update_submitted>
  <last_update_submitted_qc>November 1, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>1018 oligonucleotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: Alok.Vedvyas@nyulangone.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.</ipd_time_frame>
    <ipd_access_criteria>The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to Alok.Vedvyas@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

